Ignite Creation Date:
2024-05-06 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06195137
Status:
COMPLETED
Last Update Posted:
2024-01-08
First Post:
2023-12-03
Brief Title:
Caffeine vs ALA in BMS Treatment BMS Burning Mouth Syndrome ALA Alpha-Lipoic Acid
Sponsor:
Lu Jiang
Organization:
Sichuan University
Study Overview
Official Title:
Efficacy of Caffeine vs Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale
Detailed Description:
The etiology of BMS is multifactorial involving a complex interplay of neuropathic psychological neuroendocrine and immunological factors Neurologically BMS has been categorized into three subtypes peripheral small fiber neuropathy subclinical trigeminal neuropathy and inhibitory dopaminergic deficiency Neuroimaging and peripheral nerve studies have further implicated altered brain activation patterns and increased expression of specific receptors like TRPV1 and P2X3 in the pathogenesis of BMS Hormonal imbalances particularly in estrogen levels have also been suggested to contribute to contribute to the condition
Caffeine a xanthine alkaloid chemically known as 137-trimethylxanthine is recognized for its diverse biological functions As a central nervous system stimulant its primary mechanism involves antagonizing adenosine receptors thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine which are known to play roles in analgesic pathways Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles Additionally caffeine has mild anti-inflammatory properties Its stimulatory effects may also improve mood and cognitive function
Caffeine a xanthine alkaloid chemically known as 137-trimethylxanthine is recognized for its diverse biological functions As a central nervous system stimulant its primary mechanism involves antagonizing adenosine receptors thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine which are known to play roles in analgesic pathways Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles Additionally caffeine has mild anti-inflammatory properties Its stimulatory effects may also improve mood and cognitive function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None